Abstract:Background: Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a common respiratory disease characterized by persistent hypoxemia and an uncontrolled inflammatory response. Valsartan, an angiotensin II type 1 receptor antagonist, is clinically used to treat hypertension and has anti-inflammatory and antioxidant effects on gefitinib-induced pneumonia in rats. However, the potential therapeutic effects of valsartan on lipopolysaccharide (LPS)-induced ALI remain unclear. This study investigated the protective role of valsartan in LPS-induced ALI and its underlying mechanisms. Methods: LPS-treated BEAS-2B cells and ALI mouse model were established. BEAS-2B cells were treated with LPS (10 μg/mL) for 24h, with or without valsartan (20, 40, and 80 μM). For ALI mouse models, LPS (5 mg/kg) was administered through intratracheal injection to treat the mice for 24h, and valsartan (10 or 30 mg/kg) was injected intraperitoneally twice 2 h before and 12 h after the LPS injection. Pulmonary functional parameters were examined by an EMKA pulmonary system. Hematoxylin and eosin staining, flow cytometry, CCK-8 assay, qRT-PCR, ELISA, immunofluorescence, Western blotting, and related commercial kits were used to assess the pathological damage to the lungs, neutrophil recruitment in the lung tissue and bronchoalveolar lavage fluid (BALF), cell viability, inflammation, oxidative activity, and mucus production, respectively. Potential mechanisms were further explored using network pharmacology and Western blotting. Results: Valsartan rescued LPS-reduced cell viability of BEAS-2B cells, improved the pulmonary function, ameliorated pathological lung injury in mice with ALI, ameliorated LPS-induced neutrophil recruitment in BALF and lung tissue of mice, attenuated oxidative stress by increasing the level of SOD and decreasing that of MDA and GSSG, inhibited LPS-induced MUC5AC overproduction, decreased the LPS-induced increase in expression of pro-inflammatory cytokines/chemokines including TNF-α, IL-6, IL-1β, CXCL-1 and CXCL-2, and restored the expression of anti-inflammatory IL-10. Mechanistic studies showed that valsartan inhibits LPS-induced phosphorylation of nuclear factor-kappa B (NF-κΒ) and mitogen-activated protein kinases (MAPKs) including P38, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK) in both LPS-treated cells and the mouse model of ALI. Conclusion: Valsartan protects against LPS-induced ALI by attenuating oxidative stress, reducing MUC5AC production, and attenuating the inflammatory response that may involve MAPK and NF-κΒ pathways.

Losartan as a Reproposing Therapeutic Agent in Acute Respiratory Distress Syndrome: Modulating Inflammatory Responses and Cytokine Production

Losartan Inhibits Conventional Dendritic Cell Maturation And Th1 And Th17 Polarization Responses: Novel Mechanisms Of Preventive Effects On Lipopolysaccharide-Induced Acute Lung Injury

Losartan, a Selective Antagonist of AT1 Receptor, Attenuates Acute Lung Injury Induced by Seawater Inhalation in Rats

Losartan Modulates T Helper Type 1 Cells and T Helper Type 17 Cells-Mediated Responses in a Mouse Model of Lipopolysaccharide-Induced Acute Lung Injury

Losartan, A Selective Antagonist of At1 Receptor, Attenuates Seawater Inhalation Induced Lung Injury Via Modulating Jak2/Stats and Apoptosis in Rat

[Effects of Losartan on Pulmonary Dendritic Cells in Lipopolysaccharide- Induced Acute Lung Injury Mice].

Losartan, an Antagonist of AT1 Receptor for Angiotensin II, Attenuates Lipopolysaccharide-Induced Acute Lung Injury in Rat.

Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome

Anti-inflammatory Effect of Losartan on LPS-induced Sepsis in Rats

Losartan Attenuates Bleomycin-Induced Pulmonary Fibrosis in Rats

Synergistic Pulmonoprotective Effect of Natural Prolyl Oligopeptidase Inhibitors in In Vitro and In Vivo Models of Acute Respiratory Distress Syndrome

Intranasal Losartan Decreases Perivascular Beta Amyloid, Inflammation, and the Decline of Neurogenesis in Hypertensive Rats

[Angiotensin II type 2 receptor expression and its modulation in angiotensin II induced acute lung injury in rat].

Losartan protects against myocardial ischemia and reperfusion injury vascular integrity preservation.

Losartan Attenuates Ventilator-induced Lung Inj ury by Inhibiting NF-κB in Rats

Reduction of asymmetric dimethylarginine involved in the cardioprotective effect of losartan in spontaneously hypertensive rats.

Valsartan attenuates LPS-induced ALI by modulating NF-κB and MAPK pathways

Angiotensin II type 2 receptor agonist attenuates LPS-induced acute lung injury through modulating THP-1-derived macrophage reprogramming

Angiotensin-(1-7) attenuates lung fibrosis by way of Mas receptor in acute lung injury.

Andrographolide sulfonate attenuates alveolar hypercoagulation and fibrinolytic inhibition partly via NF-κB pathway in LPS-induced acute respiratory distress syndrome in mice

Losartan attenuates sepsis-induced cardiomyopathy by regulating macrophage polarization via TLR4-mediated NF-κB and MAPK signaling